Company Encyclopedia
View More
name
Metsera
MTSR.US
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
1.902 T
MTSR.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pfizer partners with YaoPharma for weight management treatment

    Pfizer said on Tuesday it had entered into an exclusive licensing agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, for the development and commercialization of an experimental weight management treatment.

    Reuters·
    US
    PFE
    +0.19%
    Reuters·
    US
    PFE
    +0.19%

    Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma | PFE Stock News

    Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma for the development, manufacturing, and commercialization of YP05002, a GLP-1 receptor agonist for chronic weight management. YaoPharma will complete the Phase 1 trial, and Pfizer will further develop the drug. YaoPharma will receive $150 million upfront and up to $1.935 billion in milestone payments. Pfizer plans to conduct combination studies with its other drugs. This collaboration aims to enhance Pfizer's cardiometabolic research portfolio.

    StockTitan·
    US
    PFE
    +0.19%
    StockTitan·
    US
    PFE
    +0.19%

    Metsera shareholders vote for up to $10 billion acquisition by Pfizer

    Metsera shareholders have approved Pfizer's acquisition offer worth up to $10 billion. This move allows Pfizer to enter the obesity treatment market and diversify beyond its COVID-19 portfolio. The deal values Metsera at up to $86.25 per share, with an upfront payment of $65.60 per share in cash and up to $20.65 per share contingent on drug pipeline success.

    Reuters·
    US
    MTSR
    0.00%
    US
    PFE
    +0.19%
    Reuters·
    US
    MTSR
    0.00%
    US
    PFE
    +0.19%

    Metsera Inc. Completes Merger and Delists from Nasdaq

    Metsera Inc. has completed a merger, resulting in the delisting of its common stock from Nasdaq. The company plans to deregister its shares and suspend public reporting obligations. All company officers have departed, and new directors have been appointed. Agreements with executive officers were amended to address potential excise taxes related to the transaction.

    Reuters·
    US
    MTSR
    0.00%
    Reuters·
    US
    MTSR
    0.00%

    Pfizer joins the weight-loss gold rush, vows to be a ‘formidable competitor’

    Pfizer Inc. has acquired obesity-drug developer Metsera for $10 billion, aiming to become a major player in the weight-loss drug market. CEO Albert Bourla emphasized Pfizer's commitment to innovation, comparing it to past successes like Lipitor and Viagra. The acquisition positions Pfizer to compete with popular GLP-1 drugs and aligns with the Trump administration's initiative to lower prescription drug prices. Pfizer plans to integrate its products with the TrumpRx platform, enhancing access to medications.

    FOX Business·
    US
    MTSR
    0.00%
    US
    PFE
    +0.19%
    FOX Business·
    US
    MTSR
    0.00%
    US
    PFE
    +0.19%
    © 2025 Longbridge｜Disclaimer